As the patent clock ticks towards 2026, both Novo and Lilly are likely to intensify their efforts in expanding supply chains, boosting physician engagement, and ... Nov 14
Generic semaglutide could ultimately become not just an alternative, but the new standard driven by precision manufacturing, scaled access, and cost redefined.... Aug 11
-Advertisements-